MoonLake Immunotherapeutics Expected to Post Q2 2024 Earnings of ($0.25) Per Share (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Research analysts at Lifesci Capital issued their Q2 2024 EPS estimates for MoonLake Immunotherapeutics in a research report issued on Tuesday, May 7th. Lifesci Capital analyst R. Katkhuda forecasts that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.11) per share. Lifesci Capital also issued estimates for MoonLake Immunotherapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.31) EPS and FY2024 earnings at ($1.07) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03).

MLTX has been the subject of several other reports. Wolfe Research started coverage on MoonLake Immunotherapeutics in a research report on Thursday, February 15th. They set an “outperform” rating and a $77.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $92.00 price objective on shares of MoonLake Immunotherapeutics in a report on Wednesday, March 13th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Wednesday. William Blair reaffirmed an “outperform” rating and set a $92.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday, February 26th. Finally, The Goldman Sachs Group assumed coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, April 2nd. They issued a “neutral” rating and a $62.00 price objective for the company. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $74.46.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ MLTX opened at $42.63 on Thursday. The business has a 50-day moving average of $46.03 and a 200-day moving average of $50.77. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of -56.09 and a beta of 1.29. MoonLake Immunotherapeutics has a fifty-two week low of $24.31 and a fifty-two week high of $64.98.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MLTX. Adage Capital Partners GP L.L.C. grew its position in shares of MoonLake Immunotherapeutics by 42.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,952,703 shares of the company’s stock valued at $111,304,000 after buying an additional 580,375 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of MoonLake Immunotherapeutics by 29.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,580,000 shares of the company’s stock worth $155,806,000 after buying an additional 580,001 shares during the period. Finepoint Capital LP raised its stake in MoonLake Immunotherapeutics by 170.1% during the fourth quarter. Finepoint Capital LP now owns 895,000 shares of the company’s stock worth $54,049,000 after buying an additional 563,584 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in MoonLake Immunotherapeutics by 1,270.7% in the third quarter. TimesSquare Capital Management LLC now owns 411,215 shares of the company’s stock valued at $23,439,000 after buying an additional 381,215 shares during the period. Finally, Avidity Partners Management LP boosted its position in MoonLake Immunotherapeutics by 94.3% during the third quarter. Avidity Partners Management LP now owns 777,172 shares of the company’s stock valued at $44,299,000 after acquiring an additional 377,172 shares during the last quarter. Institutional investors and hedge funds own 93.85% of the company’s stock.

Insiders Place Their Bets

In related news, insider Kristian Reich sold 10,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $60.15, for a total value of $601,500.00. Following the completion of the transaction, the insider now owns 110,071 shares of the company’s stock, valued at $6,620,770.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Kristian Reich sold 10,000 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $60.15, for a total value of $601,500.00. Following the completion of the transaction, the insider now owns 110,071 shares of the company’s stock, valued at $6,620,770.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Da Silva Jorge Santos sold 20,000 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $60.18, for a total value of $1,203,600.00. Following the completion of the transaction, the chief executive officer now owns 3,147,554 shares of the company’s stock, valued at $189,419,799.72. The disclosure for this sale can be found here. Insiders have sold a total of 166,981 shares of company stock worth $9,490,674 in the last 90 days. Company insiders own 15.27% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.